Brought to you by:
-
Carotid disease, carotid endarterectomy, carotid stenting, CMS, NESVS 2023, New England Society for Vascular Surgery, TCAR
Carotid disease: Getting to the right decision
The recent move by the Centers for Medicare & Medicaid Services (CMS) to expand coverage for carotid artery stenting brought with it the requirement for a shared decision-making interaction between physicians and patients as they establish which carotid revascularization treatment modality is best for their disease. Currently, a validated tool does not exist—but investigators at…
-
PROMISE II 12-month data show durable outcomes with the LimFlow system in no-option CLTI patients
One-year results from the PROMISE II US pivotal trial demonstrate the durability of outcomes of transcatheter arterialisation of the deep veins (TADV) using the LimFlow system (LimFlow) and that the procedure is safe and reproducible. Daniel Clair (Vanderbilt University Medical Center, Nashville, USA) recently presented the new data for the first time at VIVA 2023…
-
Researchers report 30-day outcome data for pair of investigational carotid stenting systems
Thirty-day results from two trials assessing the performance of investigational carotid artery stenting systems—the Neuroguard and the CGuard—were recently presented at VIVA 2023. Stenting with the CGuard embolic protection carotid stent system (InspireMD) in patients with carotid artery stenosis and at high risk for carotid endarterectomy (CEA) had a death (all-cause mortality), any stroke or…
-
Computer-assisted vacuum thrombectomy system for patients with pulmonary embolism demonstrates ‘rapid, statistically significant’ improvement in RV/LV ratio
Patients undergoing computer-assisted vacuum thrombectomy with the Indigo Aspiration System (Penumbra) for pulmonary embolism (PE) showed 2.7% rates of both major adverse events (MAEs) and major bleeding at 48 hours post-procedure alongside “a significant reduction” in right ventricle/left ventricle (RV/LV) ratio of 25.7%, according to an interim analysis of the STRIKE-PE study. “The STRIKE-PE dataset…
-
Six-month outcomes from phase-one trial of anti-inflammatory drug to assess benefit in acute DVT patients demonstrate ‘promise’
The open-label phase of the DEXTERITY-AFP trial investigating the Bullfrog microinfusion device—which involves the perivenous injection of the anti-inflammatory drug dexamethasone to improve patency and post-thrombotic syndrome (PTS) six months after thrombus removal in symptomatic deep vein thrombosis (DVT) patients—has shown positive results. That’s according to late-breaking data revealed during The VEINS 2023 meeting (Oct.…
-
VAM 2024 gala set for chicago’s museum of science and industry
During the vascular annual meeting that celebrates science and research, the SVS Foundation’s annual Gala will take place in a museum that also honors science. “A Night at the Museum—A Celebration of Science” is set for Friday, June 21, 2024 at Chicago’s world-famous Museum of Science and Industry. Chairs of the 2024 Gala are Michael…
-
NESVS 2023: Cambria takes over as New England SVS president
Robert Cambria, MD, recently took over as president of the New England Society for Vascular Surgery (NESVS). He was passed the presidential baton by Sean Roddy, MD, during the NESVS 2023 annual meeting, held in Boston (Oct. 6–8). Cambria is a vascular surgeon at Northern Light Health/Eastern Maine Medical Center in Bangor, Maine. Roddy is…
-
Prepare to submit research for VAM 2024
Organizing a Vascular Annual Meeting (VAM) takes a whole lot of time and a whole lot of long-range planning. Thus, members of the SVS Postgraduate Education Committee (PGEC) have already evaluated the 90 submitted proposals (an SVS record) for educational sessions at VAM 2024. And Program Committee members, who select the scientific abstracts, are looking…
-
IVC filters, NESVS 2023, New England Society for Vascular Surgery, Pulmonary embolism, Venous disease, VTE
NESVS 2023: Novel IVC filter retrieval device slashes procedural time and radiation exposure during in vivo experiments, Yale researchers report
An inferior vena cava (IVC) filter retrieval device dubbed the next-generation in removal of the venous thromboembolism-fighting tools could substantially cut procedural times and radiation exposure, according to data emerging out of in vivo testing at Yale University. The Articulating Atraumatic Grasper is the brainchild of Cassius Iyad Ochoa Chaar, MD, associate professor of vascular…
-
Vascular branding: Determining a vascular surgeon’s value
A vascular surgeon’s value includes far more than direct revenues from procedures performed, said SVS member Robert Tahara, MD, recently. He told surgeons to remember not only these direct revenues, but also the help a surgeon provides other specialties in the hospital, as well as legal savings from “near misses—rarely considered and certainly rarely acknowledged.” …